Marcos
González Díaz
Investigador hasta 2023
Publicaciones en las que colabora con Marcos González Díaz (24)
2020
-
Measures to Maintain a SARS-CoV-2 Negative Inpatient Hematological Unit in the Midst of the COVID-19 Pandemic
Frontiers in Medicine, Vol. 7
-
Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients
Blood Cancer Journal, Vol. 10, Núm. 2
2017
-
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
Leukemia, Vol. 31, Núm. 10, pp. 2094-2103
-
Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair
Journal of Hematology and Oncology, Vol. 10, Núm. 1
-
Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array
Hematological Oncology, Vol. 35, Núm. 4, pp. 746-751
2015
2014
-
Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry
Leukemia, Vol. 28, Núm. 2, pp. 391-397
-
Late differentiation syndrome in acute promyelocytic leukemia: A challenging diagnosis
Hematology Reports, Vol. 6, Núm. 4, pp. 75-77
2013
-
Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma
British Journal of Haematology, Vol. 163, Núm. 2, pp. 223-234
2012
-
SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status
Leukemia, Vol. 26, Núm. 12, pp. 2521-2529
2010
-
BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)
Annals of Hematology, Vol. 89, Núm. 5, pp. 453-458
2007
-
Hyperhomocysteinemia is a risk factor of recurrent coronary event in young patients irrespective to the MTHFR C677T polymorphism
Thrombosis Research, Vol. 119, Núm. 6, pp. 691-698
2003
-
Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning
Bone Marrow Transplantation, Vol. 31, Núm. 5, pp. 387-392
2002
-
Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation
Leukemia, Vol. 16, Núm. 8, pp. 1423-1431
-
Methylenetetrahydrofolate reductase genotype does not play a role in multiple myeloma pathogenesis
British Journal of Haematology, Vol. 117, Núm. 4, pp. 890-892
2001
-
Gene scanning of VDJH-amplified segments is a clinically relevant technique to detect contaminating tumor cells in the apheresis products of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation
Bone Marrow Transplantation, Vol. 28, Núm. 7, pp. 665-672
-
p16/INK4a gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathies
Hematology Journal, Vol. 2, Núm. 3, pp. 146-149
2000
-
De novo methylation of tumor suppressor gene p16/INK4a is a frequent finding in multiple myeloma patients at diagnosis
Leukemia, Vol. 14, Núm. 1, pp. 183-187
-
Status of methylation of p16 gene in multiple myeloma: A comparative study of three methods for its detection
Clinical Biochemistry, Vol. 33, Núm. 5, pp. 415-418
-
The detection of contaminating clonal cells in apheresis products is related to response and outcome in multiple myeloma undergoing autologous peripheral blood stem cell transplantation
Leukemia, Vol. 14, Núm. 8, pp. 1493-1499